Literature DB >> 21039366

Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson's disease.

R Constantinescu1, B Holmberg, L Rosengren, O Corneliusson, B Johnels, H Zetterberg.   

Abstract

OBJECTIVES: Cerebrospinal fluid (CSF) levels of neurofilament triplet protein (NFL), a non-specific marker of neuronal damage, are normal in Parkinson's disease (PD) but increased after brain trauma and in several neurological disorders. Using longitudinal CSF-NFL measurements as an indicator of neuronal damage, this study investigated the impact of deep brain stimulation (DBS) of the subthalamic nucleus (STN) on the brain, directly following the surgical intervention and in chronically treated patients with PD.
MATERIALS AND METHODS: CSF-NFL levels were measured consecutively in eight patients with PD before and after STN-DBS treatment.
RESULTS: CSF-NFL levels were normal prior to STN-DBS and increased sharply during the first 2 weeks post-operatively, but normalized after 12 months or more.
CONCLUSION: The STN-DBS procedure leads to an acute but limited neuronal damage, as expected. However, normal CSF-NFL levels at 12 months post-operatively and beyond suggest the absence of any long-term neuronal damage caused by long-term STN-DBS stimulation.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21039366     DOI: 10.1111/j.1600-0404.2010.01451.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  8 in total

Review 1.  Review on intermediate filaments of the nervous system and their pathological alterations.

Authors:  Claire Lépinoux-Chambaud; Joël Eyer
Journal:  Histochem Cell Biol       Date:  2013-06-08       Impact factor: 4.304

2.  The effect of lumbar puncture on the neurodegeneration biomarker neurofilament light in macaque monkeys.

Authors:  Susan E Boehnke; Emma L Robertson; Brittney Armitage-Brown; Robert G Wither; Natalia M Lyra E Silva; Andrew Winterborn; Ron Levy; Douglas J Cook; Fernanda G De Felice; Douglas P Munoz
Journal:  Alzheimers Dement (Amst)       Date:  2020-07-13

3.  Beneficial Effects of Cannabis on Blood-Brain Barrier Function in Human Immunodeficiency Virus.

Authors:  Ronald J Ellis; Scott Peterson; Mariana Cherner; Erin Morgan; Rachel Schrier; Bin Tang; Martin Hoenigl; Scott Letendre; Jenny Iudicello
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

4.  The cerebrospinal fluid proteome in HIV infection: change associated with disease severity.

Authors:  Thomas E Angel; Jon M Jacobs; Serena S Spudich; Marina A Gritsenko; Dietmar Fuchs; Teri Liegler; Henrik Zetterberg; David G Camp; Richard W Price; Richard D Smith
Journal:  Clin Proteomics       Date:  2012-03-20       Impact factor: 3.988

5.  Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.

Authors:  Julia Peterson; Magnus Gisslen; Henrik Zetterberg; Dietmar Fuchs; Barbara L Shacklett; Lars Hagberg; Constantin T Yiannoutsos; Serena S Spudich; Richard W Price
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

6.  Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.

Authors:  Helga Eyjolfsdottir; Maria Eriksdotter; Bengt Linderoth; Göran Lind; Bengt Juliusson; Philip Kusk; Ove Almkvist; Niels Andreasen; Kaj Blennow; Daniel Ferreira; Eric Westman; Inger Nennesmo; Azadeh Karami; Taher Darreh-Shori; Ahmadul Kadir; Agneta Nordberg; Erik Sundström; Lars-Olof Wahlund; Anders Wall; Maria Wiberg; Bengt Winblad; Åke Seiger; Lars Wahlberg; Per Almqvist
Journal:  Alzheimers Res Ther       Date:  2016-07-07       Impact factor: 6.982

7.  Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.

Authors:  Michael Benatar; Joanne Wuu; Caroline McHutchison; Ronald B Postuma; Bradley F Boeve; Ronald Petersen; Christopher A Ross; Howard Rosen; Jalayne J Arias; Stephanie Fradette; Michael P McDermott; Jeremy Shefner; Christine Stanislaw; Sharon Abrahams; Stephanie Cosentino; Peter M Andersen; Richard S Finkel; Volkan Granit; Anne-Laure Grignon; Jonathan D Rohrer; Corey T McMillan; Murray Grossman; Ammar Al-Chalabi; Martin R Turner
Journal:  Brain       Date:  2022-03-29       Impact factor: 15.255

8.  Cerebrospinal fluid biomarker candidates for parkinsonian disorders.

Authors:  Radu Constantinescu; Stefania Mondello
Journal:  Front Neurol       Date:  2013-01-21       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.